Advertisement

World Journal of Pediatrics

, Volume 13, Issue 4, pp 321–327 | Cite as

Effects of methylprednisolone or immunoglobulin when added to standard treatment with intravenous azithromycin for refractory Mycoplasma pneumoniae pneumonia in children

  • Li-Shen ShanEmail author
  • Xin Liu
  • Xin-Yuan Kang
  • Fei Wang
  • Xiao-Hua Han
  • Yun-Xiao Shang
Original Article

Abstract

Background

The prevalence of Mycoplasma pneumoniae pneumonia has increased considerably in recent years. To evaluate the efficacy of combined treatment of azithromycin with intravenous immunoglo-bulin (IVIG) or methylprednisolone in children with refractory Mycoplasma pneumoniae pneumonia (RMPP).

Methods

Children with RMPP were randomly allocated to group A [intravenous azithromycin (IA)+ methylprednisolone], group B (IA+IVIG) or group C (IA alone). Following a 7-day treatment, group C patients were randomly separated into two sub-groups: group C1 (IA+methylprednisolone) and group C2 (IA+IVIG). Temperature, respiratory symptoms and signs were examined. The average febrile period after treatment (F2), average total febrile period (F3), infiltration absorption, atelectasis resolution, pleural effusion disappearance were determined. The levels of C-reactive protein (CRP), D-dimer, and lactate dehydrogenase (LDH) were measured.

Results

Seven days after enrollment, the average F2 after treatment of group A was the shortest. Compared with the control group C, the combined treatment group A and B showed higher rates of infiltration absorption, atelectasis resolution and pleural effusion disappearance, while lower levels of serum CRP, D-dimer and LDH. Fourteen days after enrollment, all children with combined therapy clinically improved, and presented better laboratory results. Group C1 showed shorter F3 and lower levels of CRP and LDH than those of group C2. Overall, group A showed the shortest F3, also has the lowest CRP and LDH.

Conclusions

Azithromycin with IVIG or methylprednisolone was better treatment for children with RMPP than azithromycin alone. IVIG treatment may be beneficial, especially when the efficacy of corticosteroids is insecure, thus could be considered as an alternative of primary therapeutic approaches.

Key words

immunoglobulin methylprednisolone refractory Mycoplasma pneumoniae pneumonia 

References

  1. 1.
    Youn YS, Lee KY, Hwang JY, Rhim JW, Kang JH, Lee JS, et al. Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia. BMC Pediatr 2010;10:48.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T. Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect 2008;57:223–228.CrossRefPubMedGoogle Scholar
  3. 3.
    Luo Z, Luo J, Liu E, Xu X, Liu Y, Zeng F, et al. Effects of prednisolone on refractory mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol 2014;49:377–380.CrossRefPubMedGoogle Scholar
  4. 4.
    You SY, Jwa HJ, Yang EA, Kil HR, Lee JH. Effects of methylprednisolone pulse therapy on refractory Mycoplasma pneumoniae pneumonia in children. Allergy Asthma Immunol Res 2014;6:22–26.CrossRefPubMedGoogle Scholar
  5. 5.
    Shen Y, Zhang J, Hu Y, Shen K. Combination therapy with immune-modulators and moxifloxacin on fulminant macrolideresistant Mycoplasma pneumoniae infection: a case report. Pediatr Pulmonol 2013;48:519–522.CrossRefPubMedGoogle Scholar
  6. 6.
    Attilakos A, Palaiologou P, Lagona E, Voutsioti A, Dinopoulos A. Mycoplasma pneumoniae encephalopathy: recovery after intravenous immunoglobulin. Pediatr Neurol 2008;38:357–359.CrossRefPubMedGoogle Scholar
  7. 7.
    Bressan S, Mion T, Andreola B, Bisogno G, Da Dalt L. Severe Mycoplasma pneumoniae-associated mucositis treated with immunoglobulins. Acta Paediatr 2011;100:e238–e240.CrossRefPubMedGoogle Scholar
  8. 8.
    Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, et al. Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011;53:617–630.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Xin D, Mi Z, Han X, Qin L, Li J, Wei T, et al. Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob Agents Chemother 2009;53:2158–2159.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, et al. Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Diagn Microbiol Infect Dis 2010;67:355–358.CrossRefPubMedGoogle Scholar
  11. 11.
    Xu YC, Zhu LJ, Xu D, Tao XF, Li SX, Tang LF, et al. Epidemiological characteristics and meteorological factors of childhood Mycoplasma pneumoniae pneumonia in Hangzhou. World J Pediatr 2011;7:240–244.CrossRefPubMedGoogle Scholar
  12. 12.
    Okada T, Morozumi M, Tajima T, Hasegawa M, Sakata H, Ohnari S, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis 2012;55:1642–1649.CrossRefPubMedGoogle Scholar
  13. 13.
    Wang JY, Lee CH, Cheng SL, Chang HT, Hsu YL, Wang HC, et al. Comparison of the clinical manifestations of severe acute respiratory syndrome and Mycoplasma pneumoniae pneumonia. J Formos Med Assoc 2004;103:894–899.PubMedGoogle Scholar
  14. 14.
    Seo YH, Kim JS, Seo SC, Seo WH, Yoo Y, Song DJ, et al. Predictive value of C-reactive protein in response to macrolides in children with macrolide-resistant Mycoplasma pneumoniae pneumonia. Korean J Pediatr 2014;57:186–192.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Tanir G, Aydemir C, Yilmaz D, Tuygun N. Internal carotid artery occlusion associated with Mycoplasma pneumoniae infection in a child. Turk J Pediatr 2006;48:166–171.PubMedGoogle Scholar
  16. 16.
    Fu M, Wong KS, Lam WW, Wong GW. Middle cerebral artery occlusion after recent Mycoplasma pneumoniae infection. J Neurol Sci 1998;157:113–115.CrossRefPubMedGoogle Scholar
  17. 17.
    Snowden N, Wilson PB, Longson M, Pumphrey RS. Antiphospholipid antibodies and Mycoplasma pneumoniae infection. Postgrad Med J 1990;66:356–362.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Guo SC, Xu CW, Liu YQ, Wang JF, Zheng ZW. Changes in plasma levels of thrombomodulin and D-dimer in children with different types of Mycoplasma pneumoniae pneumonia. Zhongguo Dang Dai Er Ke Za Zhi 2013;15:619–622. [In Chinese]PubMedGoogle Scholar
  19. 19.
    Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother 2010;16:78–86.CrossRefPubMedGoogle Scholar
  20. 20.
    Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev 2008;32:956–973.CrossRefPubMedGoogle Scholar
  21. 21.
    Lee KY, Lee HS, Hong JH, Lee MH, Lee JS, Burgner D, et al. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol 2006;41:263–268.CrossRefPubMedGoogle Scholar
  22. 22.
    Weiss AK, Hall M, Lee GE, Kronman MP, Sheffler-Collins S, Shah SS. Adjunct corticosteroids in children hospitalized with community-acquired pneumonia. Pediatrics 2011;127:e255–e263.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Lin WC, Lee PI, Lu CY, Hsieh YC, Lai HP, Lee CY, et al. Mycoplasma pneumoniae encephalitis in childhood. J Microbiol Immunol Infect 2002;35:173–178.PubMedGoogle Scholar
  24. 24.
    Youn YS, Lee KY. Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr 2012;55:42–47.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Lee KY. Pediatric respiratory infections by Mycoplasma pneumoniae. Expert Rev Anti Infect Ther 2008;6:509–521.CrossRefPubMedGoogle Scholar
  26. 26.
    Yang J, Hooper WC, Phillips DJ, Talkington DF. Cytokines in Mycoplasma pneumoniae infections. Cytokine Growth Factor Rev 2004;15:157–168.CrossRefPubMedGoogle Scholar
  27. 27.
    Lu A, Wang L, Zhang X, Zhang M. Combined treatment for child refractory Mycoplasma pneumoniae pneumonia with ciprofloxacin and glucocorticoid. Pediatr Pulmonol 2011;46:1093–1097.CrossRefPubMedGoogle Scholar
  28. 28.
    Shimizu T, Kida Y, Kuwano K. Cytoadherence-dependent induction of inflammatory responses by Mycoplasma pneumoniae. Immunology 2011;133:51–61.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Tagliabue C, Salvatore CM, Techasaensiri C, Mejias A, Torres JP, Katz K, et al. The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis 2008;198:1180–1188.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Sibila O, Agusti C, Torres A. Corticosteroids in severe pneumonia. Eur Respir J 2008;32:259–264.CrossRefPubMedGoogle Scholar
  31. 31.
    Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004;17:697–728, table of contents.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Ahluwalia J, Wan J, Lee DH, Treat J, Yan AC. Mycoplasmaassociated Stevens-Johnson syndrome in children: retrospective review of patients managed with or without intravenous immunoglobulin, systemic corticosteroids, or a combination of therapies. Pediatr Dermatol 2014;31:664–669.CrossRefPubMedGoogle Scholar
  33. 33.
    Mofenson LM, Shearer WT, Moye J, Nugent R, Willoughby A. Manipulating the immune system with immune globulin. The National Institute of Child Health and Human Development. Intravenous Immunoglobulin Study Group. N Engl J Med 1992;326:1636–1637; author reply 1637-1638.Google Scholar
  34. 34.
    Krause I, Wu R, Sherer Y, Patanik M, Peter JB, Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations-a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med 2002;12:133–139.CrossRefPubMedGoogle Scholar
  35. 35.
    Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, et al. Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci 2007;1110:497–506.CrossRefPubMedGoogle Scholar

Copyright information

© Children's Hospital, Zhejiang University School of Medicine and Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Li-Shen Shan
    • 1
    Email author
  • Xin Liu
    • 1
  • Xin-Yuan Kang
    • 2
  • Fei Wang
    • 1
  • Xiao-Hua Han
    • 1
  • Yun-Xiao Shang
    • 1
  1. 1.Department of Pediatric PulmonologyShengjing Hospital of China Medical UniversityShenyangChina
  2. 2.China Medical UniversityShenyangChina

Personalised recommendations